Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
This study reinforces the noninferiority of sentinel node biopsy in patients with clinically node-negative breast cancer, offering a potential paradigm shift in surgical decision-making and patient care.
Oncology, Medical April 8th 2024
Cancer Therapy Advisor
Explore new horizons in advanced hepatocellular carcinoma treatment with emerging data on lenvatinib and cisplatin’s potential efficacy as a second-line therapy and the promising triple combination therapy showing significant response rates.
Oncology, Medical April 1st 2024
Healthgrades for Professionals
Explore key points for patient communication on chemotherapy, offering a clear framework to discuss treatment goals, processes, and side effects, enhancing patient understanding and engagement in their care journey.
Hematology/Oncology April 1st 2024
Explore the latest insights from ASCO GU 2024 on first-line treatments for advanced renal cell carcinoma, including the effectiveness of combination therapies and the pressing need to address racial disparities in patient outcomes.
OBR Oncology
Mirvetuximab soravtansine represents a pivotal shift in treating platinum-resistant ovarian cancer, demonstrating not only improved survival outcomes but also a higher response rate compared to standard chemotherapy.
MDLinx
A radiologist’s failure to detect early-stage cancer exemplifies the profound implications of diagnostic accuracy in radiology, emphasizing the necessity for vigilance in interpreting imaging studies to prevent catastrophic outcomes.